Cargando…

Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions

The role of fluoroquinolones (FQs) as empirical therapy for community-acquired pneumonia (CAP) remains controversial in countries with high tuberculosis (TB) endemicity owing to the possibility of delayed TB diagnosis and treatment and the emergence of FQ resistance in Mycobacterium tuberculosis. Al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Gwan-Han, Tsao, Thomas Chang-Yao, Kao, Shang-Jyh, Lee, Jen-Jyh, Chen, Yen-Hsu, Hsieh, Wei-Chung, Hsu, Gwo-Jong, Hsu, Yen-Tao, Huang, Ching-Tai, Lau, Yeu-Jun, Tsao, Shih-Ming, Hsueh, Po-Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. and the International Society of Chemotherapy. 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127649/ https://www.ncbi.nlm.nih.gov/pubmed/22285045 http://dx.doi.org/10.1016/j.ijantimicag.2011.11.014

Ejemplares similares

Fluoroquinolone Derivatives in the Treatment of Mycobacterium tuberculosis Infection
por: Pais, João Pedro, et al.
Publicado: (2022)

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
por: Pranger, A. D., et al.
Publicado: (2019)

Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia
por: Tseng, Yu-Tzu, et al.
Publicado: (2012)

Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation
por: Silva, Jose Tiago, et al.
Publicado: (2019)

Fluoroquinolone-Resistant Mycobacterium tuberculosis, Pakistan, 2005–2009
por: Jabeen, Kauser, et al.
Publicado: (2011)

Patterns of Fluoroquinolone Prescribing at a Tuberculosis Hospital
por: Kizilbash, Quratulain, et al.
Publicado: (2017)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Eun Hye, et al.
Publicado: (2019)

The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis
por: Castro, Rhastin A D, et al.
Publicado: (2020)

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2020)

Gemifloxacin, a Fluoroquinolone Antimicrobial Drug, Inhibits Migration and Invasion of Human Colon Cancer Cells
por: Kan, Jung-Yu, et al.
Publicado: (2013)

The Use of Fluoroquinolones for Tuberculosis in Victoria between 2011 and 2016
por: Murray, Hugh, et al.
Publicado: (2018)

Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis
por: Maranchick, Nicole F., et al.
Publicado: (2022)

High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli
por: Rattanaumpawan, Pinyo, et al.
Publicado: (2017)

Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea
por: Kang, Bo Hyoung, et al.
Publicado: (2017)

Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis
por: Hogan, Catherine A, et al.
Publicado: (2016)

Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran
por: Sayadi, Mahdieh, et al.
Publicado: (2020)

Fluoroquinolone resistant tuberculosis: A case report and literature review
por: Gill, Ajaypal, et al.
Publicado: (2019)

Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance
por: Stagg, Helen R., et al.
Publicado: (2019)

1459. Oral Cephalosporins vs. Fluoroquinolones for the Empiric Treatment of Acute Uncomplicated Pyelonephritis
por: Lin, Kevin, et al.
Publicado: (2019)

High-Resolution Melting Analysis for the Rapid Detection of Fluoroquinolone and Streptomycin Resistance in Mycobacterium tuberculosis
por: Lee, Ann S. G., et al.
Publicado: (2012)

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis
por: Coeck, Nele, et al.
Publicado: (2016)

Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations
por: Rigouts, L., et al.
Publicado: (2019)

Inclusion of minor alleles improves catalogue-based prediction of fluoroquinolone resistance in Mycobacterium tuberculosis
por: Brankin, Alice E, et al.
Publicado: (2023)

Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones
por: Migliori, Giovanni Battista, et al.
Publicado: (2012)

Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis
por: Donnellan, Samantha, et al.
Publicado: (2019)

Etymologia: Fluoroquinolone
por: Henry, Ronne
Publicado: (2017)

Prevalence, risk factors and treatment outcomes of fluoroquinolones-associated tendinopathy in tuberculosis patients at university hospital, Thailand
por: Chongboonwatana, Jirarat, et al.
Publicado: (2023)

Targeting Multidrug Resistant Mycobacterium tuberculosis HtrA2 with Identical Chemical Entities of Fluoroquinolones
por: Daisy, P., et al.
Publicado: (2012)

A novel gyrB gene mutation in fluoroquinolone resistant clinical isolates of Mycobacterium tuberculosis
por: Singh, Pooja, et al.
Publicado: (2014)

Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis
por: Li, Jing, et al.
Publicado: (2014)

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients
por: Kabir, Saba, et al.
Publicado: (2020)

Resistance patterns, prevalence, and predictors of fluoroquinolones resistance in multidrug resistant tuberculosis patients
por: Ahmad, Nafees, et al.
Publicado: (2015)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

Newer fluoroquinolones in the treatment of acute exacerbations of COPD
por: Patel, Amit, et al.
Publicado: (2006)

Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications
por: Michalak, Krzysztof, et al.
Publicado: (2017)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Do fluoroquinolones actually increase mortality in community-acquired pneumonia?
por: Agarwal, Ritesh
Publicado: (2006)

Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis
por: Anand, RS, et al.
Publicado: (2011)

1043 Fluoroquinolone Resistance in Community-acquired Acute Pyelonephritis: Clinical Characteristics, Risk Factors and Clinical Response according to Fluoroquinolone MIC of Uropathogens
por: Kim, Yeonjae, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6e4t22btgflpfflvbtnckcngin